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heterozygous animals, which normally
develop sarcomas at a higher incidence
than lymphomas, bub1 partial loss of
function had no effect on sarcoma inci-
dence. Though APCmin/+ colon tumor
incidence was similarly increased in the
bub1+/ setting, no change was seen in
the incidence of small intestinal tumors,
which are also seen in this strain. The
mechanistic basis for this context depen-
dence will require further studies. Tech-
nologies to carefully measure rates of
aneuploidy and LOH in early neoplastic
lesions will undoubtedly aid in this
analysis.
Previous studies have already sug-
gested that CIN might, in some contexts,
act as a tumor suppressor (Garcia-
Higuera et al., 2008; Rao et al., 2005;
Weaver et al., 2007). Baker et al.’s study
reinforces the notion that whether CIN
favors or prevents tumor formation and
progression is very much subject to the
setting under which it occurs. Certain
cell types may be particularly sensitive
to abnormal chromosome complements
and be eliminated in early lesions.
Whether non-cell-autonomous effects
are at play in such suppression has not
yet been analyzed. Aneuploidy in cells
of the tumor microenvironment, for
example, may contribute in some tissue
types to tumor suppression. Conditional
models of CIN will be required to address
this issue.
The finding that, in the setting of p53 or
APCmin heterozygosity, the mutant allele
is similarly duplicated strongly suggests
that there is selective pressure to maintain
two copies of the chromosome harboring
the tumor suppressor that undergoes
LOH. Haploinsufficiency of genes on this
chromosome likely decreases the fitness
of cells that have undergone such a loss,
and these cells are rapidly outcompeted
in the population.
The results presented in this issue by
Baker et al. provide the first evidence for
a potential mechanism by which CIN can
lead to tumorigenesis by linking aneu-
ploidy to loss of heterozygosity of tumor
suppressor genes. As so often happens
with important advances in cancer
biology, more questions are now raised.
Could CIN favor the duplication of chro-
mosomes harboring oncogenic mutations
at the same time as it accelerates the loss
of tumor suppressors? Does CIN occur
prior to the loss of tumor suppressors
and is it generally present in early preneo-
plastic lesions as one might predict from
the current analysis? Does such a mecha-
nism of mutant chromosome retention
occur in human cancers?
Nonetheless, this study uncovers an
important mechanistic insight into how
LOH is accelerated by defects in the
mitotic checkpoint pathway and paves
the way for a deeper understanding of
the role of CIN in cancer initiation and
progression.
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Eph receptors are important but controversial regulators of cancer development. A recent study reported in
Cell reveals that in the intestinal epithelium, EphB2 enhances proliferation through a kinase-dependent
pathway and inhibits migration independent of its kinase activity. These separate pathways simultaneously
promote proliferation but suppress invasive growth of intestinal adenomas.Extensive evidence implicates the Eph
receptor family of tyrosine kinases in can-
cer development, but it remains incom-452 Cancer Cell 16, December 8, 2009 ª200pletely understood how these receptors
affect cancer progression. Opposite
tumor-promoting and tumor-suppressing9 Elsevier Inc.effects have been described, sometimes
for the same Eph receptor in the same
type of cancer (Pasquale, 2008). Switching
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Previewsbetween opposite activities
has been attributed to contex-
tual factors, such as activa-
tion of Eph-dependent tumor
suppressor pathways by eph-
rin ligands versus hijacking of
Eph receptors by oncogenic
signaling pathways.
Eph receptors of the B
class, which bind the trans-
membrane ephrin-B ligands,
have been well studied in the
intestine. The EphB2, EphB3,
and EphB4 receptors and
the ephrin-B1 and ephrin-B2
ligands are expressed in com-
plementary gradients along
the crypts under the control
of theWnt/b-catenin/Tcfpath-
way, which upregulates EphB
and downregulates ephrin-B
expression (Batlle et al.,
2002). Thus, EphB receptors
are expressed in the prolifer-
ating progenitor cells located
near the bottom of the crypts,
close to the source of Wnt
protein. As progenitor cells
migrate toward the intestinal
lumen, they gradually lose
EphB and acquire ephrin-B
expression while they differ-
entiate before being shed.
EphB repulsive signaling
determines progenitor cell
positioning by preventing
premature migration into the
more differentiated ephrin-B
regions. Illustrating the com-
plexity of Eph functions, EphB signaling
also promotes proliferation, which is a
less common Eph activity and occurs
independently of nuclear b-catenin (Fig-
ure 1; Holmberg et al., 2006).
These dual EphB activities play an
important role in intestinal homeostasis
and tumorigenesis. In the transition from
normal cells to intestinal adenoma, EphB
receptors are usually upregulated and
ephrin-Bs downregulated by the con-
stitutive activation of the b-catenin/Tcf
pathway (Batlle et al., 2002). EphB recep-
tors are responsible for about half of the
proliferative activity in adenomas (Gen-
ander et al., 2009; Holmberg et al., 2006),
but adenoma growth is restricted by
repulsion from ephrin-Bs in the surround-
ing differentiated epithelium (Batlle et al.,
2005; Cortina et al., 2007). The EphB
proliferative effects may nevertheless
have some tumor-promoting ability, as
perhaps suggested by the decreased
tumor counts in the small intestine of
APCmin/+ mice with impaired EphB signal-
ing (Batlle et al., 2005; Cortina et al., 2007).
Although the b-catenin/Tcf pathway re-
mains active in the more malignant colo-
rectal carcinomas, EphB receptors are
lost in many of the tumor cells, enabling
invasiveness as well as tumor expansion
through EphB-independent proliferation.
This represents a critical step in the
progression to malignant stages and
correlates with a poor prognosis. Thus,
EphB receptors promote proliferation but
suppress adenoma growth.
Frisen and colleagues now shed light
on this apparent paradox (Genander
et al., 2009). They used a microarray
approach to achieve a global
view of the transcriptional
changes occurring in the
colon of mice injected with
ephrin-B2-Fc, which promis-
cuosly binds all EphB recep-
tors. In this in vivo setting,
ephrin-B2-Fc appears to
function as an EphB antago-
nist (Holmberg et al., 2006),
even though in other settings
it can act as an agonist (Noren
et al., 2006). Consistent with
the functional data, the mi-
croarray analyses reveal that
EphB receptors regulate
genes involved in both cell
proliferation and migration.
The authors resorted to
in vivo analysis of mice receiv-
ing ephrin-B2-Fc as well as
a series of mutant mice to
dissect EphB signaling path-
ways in the intestine
(Genander et al., 2009; Holm-
berg et al., 2006). Because
previous analysis of EphB2
and EphB3 knockout mice
had shown that the two
receptors have partially
redundant functions in intes-
tinal cells (Batlle et al., 2002),
various EphB2 mutants with
increased or deficient ki-
nase activity were engineered
to replace endogenous
EphB2 in an EphB3 null back-
ground. The results show that
the proliferative effects of
EphB2 require its kinase activity. Further
analyses demonstrated that EphB2 relies
on Abl kinase activation and consequent
upregulation of cyclin D1 levels to
promote proliferation (Figure 1). Abl was
previously identified as a critical effector
of the related EphB4 receptor in breast
cancer cells. However, in those cells Abl
signals by phosphorylating and inactivat-
ing the adaptor protein Crk, thereby
decreasing both proliferation and migra-
tion (Noren et al., 2006). Eph-Abl functions
may therefore vary depending on the
cellular context or the receptor involved.
It will be interesting to dissect the
signaling connection by which Abl regu-
lates cyclin D1, and why the well-charac-
terized Abl substrate Crk does not seem
to participate in EphB signaling in intes-
tinal cells. Another interesting issue is
Figure 1. EphB2 Promotes Proliferation and Inhibits Migration in
Intestinal Cells through Distinct Pathways
(Left) EphB2 interaction with ephrin-B ligands in the normal intestine increases
cyclin D1 protein levels through Abl, thereby promoting cell proliferation. In
intestinal adenomas, EphB2 is overexpressed and also promotes proliferation.
The Abl inhibitor imatinib can block these effects.
(Right) EphB2 interaction with ephrin-B ligands upregulates transcripts encod-
ing the p110a isoform of PI3 kinase and inhibits migration in a kinase-indepen-
dent manner. The PI3 kinase inhibitor LY294002 blocks these effects. It is not
known whether EphB2 may also stabilize p110 isoforms at the posttranscrip-
tional level and/or stimulate PI3 kinase activity. Other pathways may also
cooperate with PI3 kinase in EphB2-dependent repulsion. In adenomas,
EphB receptors suppress tumor progression by preventing expansion into
regions that express ephrin-B ligands.Cancer Cell 16, December 8, 2009 ª2009 Elsevier Inc. 453
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adenomas depends only on ephrin-Bs
from normal epithelium or also on low
levels of coexpressed ephrin-Bs.
The microarray data also revealed that
EphB receptors increase transcription of
p110a, the most abundant PI3 kinase
catalytic subunit isoform expressed in the
colon (Figure 1). Treatment of adenoma-
like cells and mice with the PI3 kinase
inhibitor LY294002 demonstrated a
requirement for PI3 kinase activity in
EphB-dependent repulsion. Surprisingly,
the positioning of the secretory Paneth
cells at the bottom of the crypts appears
to be regulated by EphB2 through a
kinase-independent pathway, as demon-
strated by using forms of the receptor
mutated in the kinase domain (Genander
et al., 2009; Holmberg et al., 2006). Simi-
larly, EphA8 can increase the levels of
the p110g isoform through kinase-inde-
pendent regulation of protein stability (Gu
and Park, 2003). The resulting integrin acti-
vation could provide a cell context-depen-
dent mechanism for either promoting or in-
hibiting cell migration. It will be interesting
to further characterize the interplay
between EphB2 and PI3 kinase, and
determine whether it requires the p85
subunit of PI3 kinase and involves regula-
tion of PI3 kinase catalytic activity
(Figure 1). Alternatively, EphB2 may stimu-
late a more complex migratory program
that only requires basal PI3 kinase activity
and perhaps involves Rac or E-cadherin
(Batlle et al., 2002; Cortina et al., 2007;
Miao et al., 2005). An interesting prediction
is that the EphB6 receptor, which lacks
kinase activity and is also expressed at454 Cancer Cell 16, December 8, 2009 ª200the bottom of crypts (Kosinski et al.,
2007), would possess the tumor sup-
pressing but not the proliferative activity.
The new findings have potential thera-
peutic implications. They suggest that
kinase inhibitors targeting EphB receptors
and Abl would have beneficial effects
against colorectal cancer because they
would inhibit proliferation without affect-
ing tumor confinement by ephrins. Eph
kinase inhibitors could be useful to slow
the growth of adenomas, where EphB
receptors are highly expressed. Abl kinase
inhibitors, such as imatinib, could addi-
tionally inhibit proliferation in the more
malignant carcinomas, where Abl and
cyclin D1 are still active even if uncoupled
from EphB receptors (Genander et al.,
2009). Dasatinib, another Abl inhibitor
approved for human use, also potently
inhibits Eph receptors as well as Src and
could therefore be more effective. A
caveat is that different Eph receptors may
play different roles in colorectal cancer.
For instance, it is controversial whether
EphB2/EphB3 and EphB4 have similar or
contrasting roles in the intestine (Batlle
et al., 2005; Kumar et al., 2009). Promoting
EphB kinase activity, although more chal-
lenging, could instead be useful for regen-
erative medicine.
Through a tour-de-force of in vivo
studies with a wide collection of mouse
models, Genander et al. highlight a new
facet of the complex Eph roles in cancer
cells: the ability to simultaneously activate
distinct pathways with contrasting
effects. The novel signaling connections
identified in an in vivo physiological
context may involve multiple steps and9 Elsevier Inc.additional aspects that will be important
to dissect further. The role of ‘‘reverse’’
signals transduced by the transmem-
brane ephrin-Bs in intestinal cells also
awaits investigation.
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